ANK-202

ANK-202 is an investigational monoclonal antibody targeting the CD28 costimulatory receptor, currently in the discovery stage for the treatment of solid tumors. Developed by Ankyra Therapeutics, the drug is part of a pipeline utilizing a localized "anchored" immunotherapy platform designed to concentrate therapeutic agents within the tumor microenvironment. By targeting CD28, ANK-202 aims to provide the necessary second signal for T-cell activation, potentially enhancing the anti-tumor immune response while minimizing systemic side effects often associated with systemic costimulatory agonists. The anchored approach typically involves intratumoral administration to ensure high local concentrations and reduced systemic exposure.